Curium Partners with Oncidium Foundation to Support Access to Radioligand Therapy

Curium has partnered with the Oncidium Foundation to support the RLT-Connect program, a global initiative focused on expanding access to radioligand therapy (RLT) for cancer patients facing financial barriers to treatment.

The agreement was signed in Istanbul during the Belgian Economic Mission to Türkiye, led by Her Majesty Queen Mathilde of Belgium.

Through the partnership, Curium will support the RLT-Connect supply chain as one of the program’s main suppliers of lutetium-177 (Lu-177) medical radioisotopes and ready-to-use ^177Lu-PSMA radiopharmaceuticals.

Curium’s manufacturing and distribution expertise will help support the availability of these radiopharmaceuticals for patients in countries where access to advanced cancer treatments can be limited.

“This partnership is a key step in continuing the chain of solidarity that RLT-Connect depends on. Having Curium on board strengthens our ability to ensure donation of radiopharmaceuticals for underserved patients,” said Dr. Alice Fialho Viana, Scientific Director at the Oncidium Foundation.

For Curium, the collaboration reflects its broader commitment to supporting access to nuclear medicine and using its global capabilities to help address unmet healthcare needs.

“Our legacy of leadership in nuclear medicine means we have a vital role to play in driving health impact at scale for patients with cancer,” said Renaud Dehareng, CEO of Curium Group. “Using our expertise, global partnerships, and strategic access programs, we are making our products accessible to patients globally.”

The partnership brings together the expertise and capabilities of both organisations to support a shared ambition: helping make innovation in nuclear medicine and radioligand therapy more accessible to patients around the world.